Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VIR BIOTECHNOLOGY, INC.

(VIR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Oil edges higher on waning fears of Omicron's effects

12/08/2021 | 03:49pm EST
FILE PHOTO: Crude oil storage tanks are seen from above at the Cushing oil hub in Cushing

NEW YORK (Reuters) -Oil prices ended higher in a back-and-forth session on Wednesday, maintaining a positive tone as investors no longer expect the Omicron coronavirus variant to derail global economic growth.

Brent crude futures settled at $75.82, up 38 cents, or 0.5%. U.S. West Texas Intermediate crude ended at $72.36 a barrel, up 31 cents or 0.4%.

Global benchmark Brent has rebounded by about 10% since Dec. 1 on the expectation that Omicron will have only a limited impact on oil demand, after a 16% drop since Nov. 25. Early studies suggest two shots of the Pfizer-BioNTech shot may protect only partially against Omicron, but a third dose https://www.reuters.com/business/healthcare-pharmaceuticals/biontech-pfizer-say-test-shows-3-doses-vaccine-neutralise-omicron-2021-12-08 may improve that protection.

"Some of those Omicron oil demand-related concerns might have been too pessimistic, and hence with some positive news related to Omicron being released in recent days, oil prices recovered," said Giovanni Staunovo, commodity analyst at UBS.

The market had a muted reaction to U.S. weekly inventory figures. Crude stocks fell by 240,000 barrels and gasoline and distillate stocks increased as refiners picked up production. At the same time, however, U.S. product supplied by refineries, a proxy for demand, hit 20.9 million barrels per day over the past four weeks - exceeding pre-pandemic rates of consumer use.

The market expects that supply will exceed demand by early 2022, due to rising U.S. production and ongoing supply additions from the Middle East.

Ultimately, the Organization of the Petroleum Exporting Countries and its allies including Russia, known as OPEC+, chose to maintain its schedule of boosting supply by 400,000 bpd every month - despite fears that the new variant would sap demand.

The White House and Tehran have restarted talks over Iran's nuclear program, but an agreement to revive the 2015 deal that limited Iran's nuclear development is still far off, and Western officials have voiced dismay https://www.reuters.com/world/middle-east/iran-nuclear-talks-seen-resuming-thursday-france-discouraged-2021-12-07 at sweeping Iranian demands.

Tensions between Western powers and Russia over Ukraine also remained high after U.S. President Joe Biden warned Russian President Vladimir Putin on Tuesday that the West would impose "strong economic and other measures https://www.reuters.com/markets/currencies/biden-putin-set-crucial-call-over-ukraine-2021-12-07" on Russia if it invades Ukraine, while Putin demanded guarantees that NATO would not expand farther eastward.

"All of these hot spots tells the marketplace we have added risk and when we do, prices go up," said Tim Snyder, economist at Matador Economics in Dallas.

(Additional reporting by Laura Sanicola and Ron Bousso; editing by David Evans, Marguerita Choy and Lisa Shumaker)

By David Gaffen


ę Reuters 2021
All news about VIR BIOTECHNOLOGY, INC.
01/24U.S. FDA limits use of Regeneron, Lilly COVID-19 antibody treatments
RE
01/24U.S. FDA to restrict use of Regeneron, Lilly COVID antibody drugs - WaPo
RE
01/24UK to begin testing Merck's COVID pill for hospitalized patients
RE
01/23GlaxoSmithKline, Vir to Set Up New Plant to Boost Production of COVID-19 Treatment
MT
01/21GSK, Vir ramping up U.S. output of COVID antibody drug
RE
01/14WHO recommendation on Merck's oral pill likely in early February
RE
01/13GSK-Vir, Eli Lilly's COVID-19 Treatments Recommended by WHO
MT
01/13WHO recommends Eli Lilly, GSK-Vir's drugs, widening COVID-19 treatment pool
RE
01/13GSK, Vir Biotechnology Seek US FDA's Nod to Amend Emergency Use Authorization for COVID..
MT
01/13Vir Biotechnology to Get Investment, Grant From Gates Foundation for HIV, Malaria Resea..
MT
More news
Analyst Recommendations on VIR BIOTECHNOLOGY, INC.
More recommendations
Financials (USD)
Sales 2021 696 M - -
Net income 2021 233 M - -
Net cash 2021 912 M - -
P/E ratio 2021 17,9x
Yield 2021 -
Capitalization 4 091 M 4 091 M -
EV / Sales 2021 4,57x
EV / Sales 2022 2,17x
Nbr of Employees 395
Free-Float 86,9%
Chart VIR BIOTECHNOLOGY, INC.
Duration : Period :
Vir Biotechnology, Inc. Technical Analysis Chart | VIR | US92764N1028 | MarketScreener
Technical analysis trends VIR BIOTECHNOLOGY, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 31,26 $
Average target price 91,43 $
Spread / Average Target 192%
EPS Revisions
Managers and Directors
George A. Scangos President, Chief Executive Officer & Director
Howard Horn CFO, Secretary & Principal Accounting Officer
Vicki L. Sato Non-Executive Chairman
Michael E. Kamarck Chief Technology Officer
Phil Pang Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
VIR BIOTECHNOLOGY, INC.-25.34%4 091
MODERNA, INC.-41.48%60 258
LONZA GROUP AG-19.46%48 939
IQVIA HOLDINGS INC.-17.77%44 321
SEAGEN INC.-20.50%22 475
ICON PUBLIC LIMITED COMPANY-17.13%20 892